Skip to main content

AstraZeneca says disappointed with FDA Lynparza vote outcome

AstraZeneca said the FDA committee voted 11 to one, with one abstaining, to limit its Lynparza treatment to patients whose tumors have a breast cancer gene, or BRCA, mutation.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.